Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: Histopathologic findings of a patient affected by multiple myeloma

Giovanni Borroni, Camilla Vassallo, Valeria Brazzelli, Sara Martinoli, Marco Ardigò, Paolo Emilio Alessandrino, Riccardo Giovanni Borroni, Pietro Franchini

Research output: Contribution to journalArticlepeer-review

Abstract

Radiation recall dermatitis is one of the skin sequelae that may affect oncology patients. It occurs in a previously irradiated field, when subsequent chemotherapy is given. The eruption may be elicited by chemotherapy, even several months after radiotherapy. Its mechanism is poorly understood, and the histopathologic findings have received, to date, only sketchy descriptions. A 55-year-old male affected by multiple myeloma received radiation therapy both on his left coxofemoral area, and lumbar region (D11-L1). After cyclophosphamide administration, he developed 2 well defined square-shaped, infiltrated erythematoviolaceous plaques in the prior irradiated fields. Histopathologic findings revealed a diffusely fibrosclerosing process, involving deep dermis, hypodermis, as well as the underlying muscle, while sparing the epidermis and superficial-mid dermis. Histopathology was indistinguishable from deep radio-dermatitis, panniculitis, and myositis. This is the first case providing clear evidence of the causative role of cyclophosphamide in inducing a cutaneous and subcutaneous radiation recall reaction.

Original languageEnglish
Pages (from-to)213-216
Number of pages4
JournalAmerican Journal of Dermatopathology
Volume26
Issue number3
DOIs
Publication statusPublished - Jun 2004

Keywords

  • Cyclophosphamide
  • Histopathologic findings
  • Myositis
  • Panniculitis
  • Radiation recall dermatitis

ASJC Scopus subject areas

  • Dermatology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: Histopathologic findings of a patient affected by multiple myeloma'. Together they form a unique fingerprint.

Cite this